Skip to main content
. 2016 Sep 29;115(10):1223–1233. doi: 10.1038/bjc.2016.313

Figure 6.

Figure 6

FOXO3a and p38 are expressed in cetuximab-responder patients. (A) Box plot depiction of FOXO3a and p38 (MAPK14) mRNA expression in CRC samples from patients with mCRC harbouring WT KRAS and treated with cetuximab monotherapy (Khambata-Ford et al (2007); GSE5851 data set). R, cetuximab responders (n=20) and NR, cetuximab non-responders (n=19). (B) Box plot representation of FOXO3a and p38 (MAPK14) mRNA expression in the same CRC samples described in A and classified according to the molecular classifications by Marisa et al (2013) (upper panels), Sadanandam et al (2013) (middle panels) and De Sousa et al (2013) (lower panels).